Vaccitech, a clinical-stage T cell immunotherapy company developing viral vectors as vaccines to treat and prevent cancer and infectious diseases, announces today that it has appointed Mariem Charafeddine as its new chief medical officer.
Mariem brings over 15 years’ experience in the biopharmaceutical industry, spent both advancing the clinical development and commercialisation of infectious disease products, and in delivering post-marketing monitoring of licensed medical products. She has also previously worked in international medical leadership roles and drug development in infectious diseases.
“We are delighted to have Mariem join our team as we advance towards the Phase IIb read-outs of our lead clinical program in influenza,” said Tom Evans, Vaccitech CEO.
He continued, “Her wide-ranging clinical development and post-marketing expertise in infectious diseases also puts us in great stead ahead of first in human studies for our HPV and HBV therapeutics. We look forward to her input on how best to develop our vaccines for the patients that need them.”
By: Anna Smith
Source: Pharma Times
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
